(Q26852564)

M. Schmidinger

series ordinal

2

1 reference

language of work or name

1 reference

December 2013

1 reference

1 reference

24

1 reference

PubMed

issue

12

1 reference

PubMed

page(s)

2935-42

1 reference

Sunitinib in patients with metastatic renal cell carcinoma

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Hypothyroidism in patients with renal cell carcinoma: blessing or curse?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Autocrine VEGF signaling is required for vascular homeostasis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Pazopanib for the treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Sunitinib and Hypothyroidism

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Sirolimus-associated pulmonary toxicity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Sunitinib, a Receptor Tyrosine Kinase Inhibitor, Increases Blood Pressure in Rats without Associated Changes in Cardiac Structure and Function

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

New insights into molecular mechanisms of sunitinib-associated side effects

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Mechanisms of hypertension associated with BAY 43-9006.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT288

7 January 2021

Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma

1 reference